Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HLCS | P50747 | 6/20 | 0.54 |
| ▸ | CA12 | O43570 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053200 | 1.00 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL912652 | 0.91 | TDP1 (0.74) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL15647842 | 0.90 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2536441 | 0.89 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| Hydrochloric Acid SCHEMBL3417755 | 0.88 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL6040739 | 0.86 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL20417372 | 0.85 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12372458 | 0.85 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL28084581 | 0.85 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23745168 | 0.85 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376307-B2 | Compositions and methods of treating cancer with glycomimetic peptides | SUSAVION BIOSCIENCES, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210069285-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH GLYCOMIMETIC PEPTIDES | WILD BOAR BIOSCIENCES, LLC | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069285-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH GLYCOMIMETIC PEPTIDES | NGLY1, LNPEP, CD47 | TDP1 2449/4885MEN1 640/4885ABL1 482/4885 |
| US-11376307-B2 | Compositions and methods of treating cancer with glycomimetic peptides | NGLY1, LNPEP, CD47 | TDP1 2449/4885MEN1 640/4885ABL1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.